HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer

Cancer Treatment Reviews

Volumn 38, Issue 2, 2012, Pages 133-142

  Tsé, Chantal ^a   Gauchez, Anne Sophie ^b   Jacot, William ^c   Lamy, Pierre Jean ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

Breast cancer; ELISA; HER2 ECD; Oncogene Protein HER2; Predictive value of tests; Serum HER2; Shedding; Tumor markers

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ACCURACY; BIOLOGY; BREAST CANCER; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DIMERIZATION; EPITHELIUM CELL; HUMAN; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; PREVALENCE; PRIMARY TUMOR; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; QUALITY CONTROL; REVIEW; TREATMENT RESPONSE;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84856340091     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.03.008     Document Type: Review

References (113)

1. Arribas J., Borroto A. Protein ectodomain shedding. Chem Rev 2002, 102(12):4627-4638.
2. Yuan C.X., Lasut A.L., Wynn R., Neff N.T., Hollis G.F., Ramaker M.L., et al. Purification of Her-2 extracellular domain and identification of its cleavage site. Protein Expr Purif 2003, 29(2):217-222.
3. 2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998, 58(22):5123-5129.
4. Doherty J.K., Bond C., Jardim A., Adelman J.P., Clinton G.M. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci USA 1999, 96(19):10869-10874.
5. Scott G.K., Robles R., Park J.W., Montgomery P.A., Daniel J., Holmes W.E., et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993, 13(4):2247-2257.
6. Carney W.P., Neumann R., Lipton A., Leitzel K., Ali S., Price C.P. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer 2004, 5(2):105-116.
7. Ali S.M., Leitzel K., Lipton A., Carney W.P., Kostler W.J. Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials. J Clin Oncol 2009, 27(36):e273. (author reply e274-5).
8. Tse C., Lamy P.J. Clinical utility of serum human epidermal growth factor receptor 2 extracellular domain levels: stop the shilly-shally-it is time for a well-designed, large-scale prospective study. J Clin Oncol 2009, 27(36):e286-287.
9. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2):127-137.
10. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7(7):505-516.
11. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16(7):1647-1655.
12. Press M.F., Cordon-Cardo C., Slamon D.J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990, 5(7):953-962.
13. Mielke S., Meden H., Kuhn W. Expression of the c-erbB-2-encoded oncoprotein p185 (HER-2/neu) in pregnancy as a model for oncogene-induced carcinogenesis. Med Hypotheses 1998, 50(5):359-362.
14. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001, 61(Suppl 2):1-13.
15. Lin Y.Z., Clinton G.M. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 1991, 6(4):639-643.
16. Anido J., Scaltriti M., Bech Serra J.J., Santiago Josefat B., Todo F.R., et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006, 25(13):3234-3244.
17. Pedersen K., Angelini P.D., Laos S., Bach-Faig A., Cunningham M.P., Ferrer-Ramon C., et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009, 29(12):3319-3331.
18. Garcia-Castillo J., Pedersen K., Angelini P.D., Bech-Serra J.J., Colome N., Cunningham M.P. HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation. J Biol Chem 2009, 284(37):25302-25313.
19. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421(6924):756-760.
20. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P., Leahy D.J. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003, 12(3):541-552.
21. Lemmon M.A. Ligand-induced ErbB receptor dimerization. Exp Cell Res 2009, 315(4):638-648.
22. Pupa S.M., Menard S., Morelli D., Pozzi B., De Palo G., Colnaghi M.I. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 1993, 8(11):2917-2923.
23. Zabrecky J.R., Lam T., McKenzie S.J., Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991, 266(3):1716-1720.
24. Segatto O., King C.R., Pierce J.H., Di Fiore P.P., Aaronson S.A. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 1988, 8(12):5570-5574.
25. Saez R., Molina M.A., Ramsey E.E., Rojo F., Keenan E.J., Albanell J., et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006, 12(2):424-431.
26. Sanderson M.P., Dempsey P.J., Dunbar A.J. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors 2006, 24(2):121-136.
27. Reiss K., Saftig P. The " a disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions. Semin Cell Dev Biol 2009, 20(2):126-137.
28. Duffy M.J., McKiernan E., O'Donovan N., McGowan P.M. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009, 15(4):1140-1144.
29. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
30. Burns D.M., He C., Li Y., Scherle P., Liu X., Marando C.A., et al. Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations. Bioorg Med Chem Lett 2008, 18(2):560-564.
31. Bao W., Fu H.J., Jia L.T., Zhang Y., Li W., Jin B.Q., et al. HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion. Arch Biochem Biophys 2010, 499(1-2):49-55.
32. Matthews V., Schuster B., Schutze S., Bussmeyer I., Ludwig A., Hundhausen C., et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003, 278(40):38829-38839.
33. Codony-Servat J., Albanell J., Lopez-Talavera J.C., Arribas J., Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999, 59(6):1196-1201.
34. Vazquez-Martin A., Fernandez-Real J.M., Oliveras-Ferraros C., Navarrete J.M., Martin-Castillo B., Del Barco S., et al. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. Int J Oncol 2009, 35(6):1369-1376.
35. Nagy P., Vereb G., Sebestyen Z., Horvath G., Lockett S.J., Damjanovich S., et al. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci 2002, 115(Pt 22):4251-4262.
36. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007, 7(10):763-777.
37. Kumar-Sinha C., Ignatoski K.W., Lippman M.E., Ethier S.P., Chinnaiyan A.M. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 2003, 63(1):132-139.
38. Blobel C.P., Carpenter G., Freeman M. The role of protease activity in ErbB biology. Exp Cell Res 2009, 315(4):671-682.
39. Aigner A., Juhl H., Malerczyk C., Tkybusch A., Benz C.C., Czubayko F. Expression of a truncated 100kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene 2001, 20(17):2101-2111.
40. Koletsa T., Kotoula V., Karayannopoulou G., Nenopoulou E., Karkavelas G., Papadimitriou C.S., et al. EGFR expression and activation are common in HER2 positive and triple-negative breast tumours. Histol Histopathol 2010, 25(9):1171-1179.
41. Baselga J., Albanell J., Molina M.A., Arribas J., et al. Mechanism of action of trastuzumab and scientific update. Semin Oncol 2001, 28(5 Suppl 16):4-11.
42. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001, 61(12):4744-4749.
43. Scaltriti M., Chandarlapaty S., Prudkin L., Aura C., Jimenez J., Angelini P.D., et al. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 2010, 16(9):2688-2695.
44. Vazquez-Martin A., Oliveras-Ferraros C., Cufi S., Barco S.D., Martin-Castillo B., Menendez J.A., et al. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. J Cell Physiol 2010, 226(1):52-57.
45. Ghedini G.C., Ciravolo V., Tortoreto M., Giuffre S., Bianchi F., Campiglio M., et al. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. J Cell Physiol 2010, 225(1):256-265.
46. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369(9555):29-36.
47. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17(9):2639-2648.
48. Perez E.A., Roche P.C., Jenkins R.B., Reynolds C.A., Halling K.C., Ingle J.N., et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002, 77(2):148-154.
49. Sauter G., Lee J., Bartlett J.M., Slamon D.J., Press M.F. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009, 27(8):1323-1333.
50. Lamy P.J., Nanni I., Fina F., Bibeau F., Romain S., Dussert C., et al. Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer. Int J Biol Markers 2006, 21(1):20-29.
51. Tse C., Brault D., Gligorov J., Antoine M., Neumann R., Lotz J.P., et al. Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin Chem 2005, 51(7):1093-1101.
52. Lamy P.J., Verjat T., Paye M., Servanton A.C., Grenier J., Leissner P., et al. NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer. Clin Chem Lab Med 2006, 44(1):3-12.
53. Ross J.S. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News Perspect 2009, 22(2):93-106.
54. Esteva F.J., Yu D., Hung M.C., Hortobagyi G.N. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 2010, 7(2):98-107.
55. Desmedt C., Sperinde J., Piette F., Huang W., Jin X., Tan Y., et al. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol 2009, 18(1):22-29.
56. Sturgeon C.M., Hoffman B.R., Chan D.W., Ch'ng S.L., Hammond E., Hayes D.F., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice. quality requirements. Clin Chem 2008, 54(8):e1-e10.
57. Carney W.P., Neumann R., Lipton A., Leitzel K., Ali S., Price C.P. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003, 49(10):1579-1598.
58. McKenzie S.J., Marks P.J., Lam T., Morgan J., Panicali D.L., Trimpe K.L., et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 1989, 4(5):543-548.
59. Molina R., Jo J., Filella X., Bruix J., Castells A., Hague M., et al. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumour Biol 1997, 18(3):188-196.
60. Perik P.J., de Vries E.G., Gietema J.A., Van der Graaf W.T., Smilde T.D., Sleijfer D.T., et al. Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail 2007, 9(2):173-177.
61. Tse C., Lefevre G., Berkane N., Flahault A., Toumi K., Brault D., et al. Increased serum maternal levels of the HER2 oncoprotein p105 ectodomain in preeclampsia. Clin Chem Lab Med 2004, 42(2):142-146.
62. Asgeirsson K.S., Agrawal A., Allen C., Hitch A., Ellis I.O., Chapman C., et al. Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res 2007, 9(6):R75.
63. Ludovini V., Gori S., Colozza M., Pistola L., Rulli E., Floriani I., et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol 2008, 19(5):883-890.
64. Molina R., Auge J.M., Escudero J.M., Filella X., Zanon G., Pahisa J., et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol 2010, 31(3):171-180.
65. Ali S.M., Leitzel K., Chinchilli V.M., Engle L., Demers L., Harvey H.A., et al. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 2002, 48(8):1314-1320.
66. Bramwell V.H., Doig G.S., Tuck A.B., Wilson S.M., Tonkin K.S., Tomiak A., et al. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Res Treat 2009, 114(3):503-511.
67. Fehm T., Becker S., Duerr-Stoerzer S., Sotlar K., Mueller V., Wallwiener D., et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 2007, 9(5):R74.
68. Fornier M.N., Seidman A.D., Schwartz M.K., Ghani F., Thiel R., Norton L., et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005, 16(2):234-239.
69. Kong S.Y., Nam B.H., Lee K.S., Kwon Y., Lee E.S., Seong M.W., et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem 2006, 52(8):1510-1515.
70. Schwartz M.K., Smith C., Schwartz D.C., Dnistrian A., Neiman I. Monitoring therapy by serum HER-2/neu. Int J Biol Markers 2000, 15(4):324-329.
71. Souder C., Leitzel K., Ali S.M., Demers L., Evans D.B., Chaudri-Ross H.A., et al. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. Cancer 2006, 107(10):2337-2345.
72. Witzel I., Thomssen C., Krenkel S., Wilczak W., Bubenheim M., Pantel K., et al. Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer. Int J Biol Markers 2006, 21(3):131-140.
73. Cook G.B., Neaman I.E., Goldblatt J.L., Cambetas D.R., Hussain M., Luftner D., et al. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res 2001, 21(2B):1465-1470.
74. Jensen B.V., Johansen J.S., Price P.A. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003, 9(12):4423-4434.
75. Lipton A., Ali S.M., Leitzel K., Demers L., Chinchilli V., Engle L., et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002, 20(6):1467-1472.
76. Lipton A., Ali S.M., Leitzel K., Demers L., Harvey H.A., Chaudri-Ross H.A. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003, 21(10):1967-1972.
77. Johnston S, O'Rourke L, Wang W, Pegram M, Press M, Maltzman J. Correlation of tumor burden, liver and bone metastasis with serum extracellular domain HER-2 expression in front-line metastatic breast cancer. Cancer Res 2009;69:Abstract # 3146.
78. Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., Ravdin P.M., Hortobagyi G.N. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14(4):320-368.
79. Witzel I., Loibl S., von Minckwitz G., Mundhenke C., Huober J., Hanusch C., et al. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat 2010, 123(2):437-445.
80. Dresse M, Mayr D, Heinemann V, Kahlert S, Bauerfeind I, Nagel D, et al. HER-2/neu in tissue and serum at time of primary breast cancer. J Clin Oncol 2009:Abstract #11500.
81. Leary A.F., Hanna W.M., Van de Vijver M.J., Penault-Llorca F., Ruschoff J., Osamura R.Y., et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 2009, 27(10):1694-1705.
82. Broom R.J., Tang P.A., Simmons C., Bordeleau L., Mulligan A.M., O'Malley F.P., et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009, 29(5):1557-1562.
83. Santiago M.P., Vazquez-Boquete A., Fernandez B., Masa C., Antunez J.R., Fraga M. Whether to determine HER2 status for breast cancer in the primary tumour or in the metastasis. Histol Histopathol 2009, 24(6):675-682.
84. Wilking U., Karlsson E., Skoog L., Hatschek T., Lidbrink E., Elmberger G., et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 2010, 125(2):553-561.
85. Sari E., Guler G., Hayran M., Gullu I., Altundag K., Ozisik Y. Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 2010, 28(1):57-63.
86. Regitnig P., Schippinger W., Lindbauer M., Samonigg H., Lax S.F. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 2004, 203(4):918-926.
87. Cho E.Y., Han J.J., Choi Y.L., Kim K.M., Oh Y.L. Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study. J Korean Med Sci 2008, 23(6):1053-1061.
88. Lower E.E., Glass E., Blau R., Harman S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009, 113(2):301-306.
89. Santinelli A., Pisa E., Stramazzotti D., Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008, 122(5):999-1004.
90. Zidan J., Dashkovsky I., Stayerman C., Basher W., Cozacov C., Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005, 93(5):552-556.
91. Guarneri V., Giovannelli S., Ficarra G., Bettelli S., Maiorana A., Piacentini F., et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008, 13(8):838-844.
92. Luftner D., Cheli C., Mickelson K., Sampson E., Possinger K. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer. Int J Biol Markers 2004, 19(3):175-182.
93. Meng S., Tripathy D., Shete S., Ashfaq R., Haley B., Perkins S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004, 101(25):9393-9398.
94. Kmieciak M., Knutson K.L., Dumur C.I., Manjili M.H. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol 2007, 37(3):675-685.
95. Arslan C., Sari E., Aksoy S., Altundag K. Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets 2011, 15(1):21-30.
96. Harris L.N., Liotcheva V., Broadwater G., Ramirez M.J., Maimonis P., Anderson S., et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001, 19(6):1698-1706.
97. Saghatchian M., Guepratte S., Hacene K., Neumann R., Floiras J.L., Pichon M.F. Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers 2004, 19(1):14-22.
98. Sorensen P.D., Jakobsen E.H., Langkjer S.T., Bokmand S., Ostergaard B., Olsen D.A. Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. Clin Chem Lab Med 2009, 47(9):1117-1123.
99. Nahta R., Shabaya S., Ozbay T., Rowe D.L. Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmacogenomics Person Med 2009, 7(4):263-274.
100. Kostler W.J., Steger C.G., Soleiman A., Schwab B., Singer C.F., Tomek S., et al. Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. Anticancer Res 2004, 24(2C):1127-1130.
101. Mazouni C., Hall A., Broglio K., Fritsche H., Andre F., Esteva F.J., et al. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 2007, 109(3):496-501.
102. Ardavanis A., Kountourakis P., Kyriakou F., Malliou S., Mantzaris I., Garoufali A. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist 2008, 13(4):361-369.
103. Kostler W.J., Schwab B., Singer C.F., Neumann R., Rucklinger E., Brodowicz T. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004, 10(5):1618-1624.
104. Esteva F.J., Cheli C.D., Fritsche H., Fornier M., Slamon D., Thiel R.P., et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 2005, 7(4):R436-443.
105. Ali S.M., Carney W.P., Esteva F.J., Fornier M., Harris L., Kostler W.J., et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 2008, 113(6):1294-1301.
106. Gasparini G., Gion M., Mariani L., Papaldo P., Crivellari D., Filippelli G., et al. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 2007, 101(3):355-365.
107. Hudelist G., Kostler W.J., Gschwantler-Kaulich D., Czerwenka K., Kubista E., Muller R., et al. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Eur J Cancer 2006, 42(2):186-192.
108. Bethune-Volters A., Labroquere M., Guepratte S., Hacene K., Neumann R., Carney W., et al. Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients. Anticancer Res 2004, 24(2C):1083-1089.
109. Cameron D., Casey M., Press M., Lindquist D., Pienkowski T., Romieu C.G., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112(3):533-543.
110. Finn R.S., Gagnon R., Di Leo A., Press M.F., Arbushites M., Koehler M. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol 2009, 27(33):5552-5558.
111. Gomez H.L., Doval D.C., Chavez M.A., Ang P.C., Aziz Z., Nag S., et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008, 26(18):2999-3005.
112. Sandri M.T., Johansson H., Colleoni M., Zorzino L., Passerini R., Orlando L., et al. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res 2004, 24(2C):1261-1266.
113. Fehm T., Jager W., Kraemer S., Sohn C., Solomayer-Meyberg G., Solomayer E.F., et al. Changes of serum HER2 status during clinical course of metastatic breast cancer patients. Anticancer Res 2004, 24(6):4205-4210.